JP2008508858A5 - - Google Patents

Download PDF

Info

Publication number
JP2008508858A5
JP2008508858A5 JP2007513435A JP2007513435A JP2008508858A5 JP 2008508858 A5 JP2008508858 A5 JP 2008508858A5 JP 2007513435 A JP2007513435 A JP 2007513435A JP 2007513435 A JP2007513435 A JP 2007513435A JP 2008508858 A5 JP2008508858 A5 JP 2008508858A5
Authority
JP
Japan
Prior art keywords
seq
antibody
pharmaceutical composition
fragment
antibody comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007513435A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008508858A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/016920 external-priority patent/WO2005120557A2/en
Publication of JP2008508858A publication Critical patent/JP2008508858A/ja
Publication of JP2008508858A5 publication Critical patent/JP2008508858A5/ja
Pending legal-status Critical Current

Links

JP2007513435A 2004-05-13 2005-05-13 マクロファージ−刺激タンパク質受容体（ｒｏｎ）の阻害 Pending JP2008508858A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57164804P 2004-05-13 2004-05-13
PCT/US2005/016920 WO2005120557A2 (en) 2004-05-13 2005-05-13 Inhibition of macrophage-stimulating protein receptor (ron)

Publications (2)

Publication Number Publication Date
JP2008508858A JP2008508858A (ja) 2008-03-27
JP2008508858A5 true JP2008508858A5 (enExample) 2008-07-03

Family

ID=35503660

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007513435A Pending JP2008508858A (ja) 2004-05-13 2005-05-13 マクロファージ−刺激タンパク質受容体（ｒｏｎ）の阻害

Country Status (5)

Country Link
US (1) US20090246205A1 (enExample)
EP (1) EP1773881A4 (enExample)
JP (1) JP2008508858A (enExample)
CA (1) CA2566647A1 (enExample)
WO (1) WO2005120557A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008029807A1 (fr) * 2006-09-06 2008-03-13 Japan Science And Technology Agency Nouveau polypeptide ayant une cytotoxicité contre le cancer, procédé pour cribler le polypeptide et utilisation du polypeptide
BRPI0813262A2 (pt) * 2007-06-20 2015-04-14 Schering Corp Biomarcadores de destruição de articulação para terapia de doença inflamatória de articulação anti-il-17a
UY31478A1 (es) * 2007-11-21 2009-07-17 Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo
US20090202570A1 (en) * 2007-12-21 2009-08-13 Patrys Limited Pm-2 antibodies, functional fragments and methods for treating metastasis
US20090226442A1 (en) * 2008-01-22 2009-09-10 Biogen Idec Ma Inc. RON antibodies and uses thereof
EP2282769A4 (en) 2008-04-29 2012-04-25 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
WO2010014751A2 (en) * 2008-07-29 2010-02-04 Texas Tech University Monoclonal antibody zt/2f2 in targeted therapy of cancers overexpressing the ron receptor tyrosine kinase
TWI480050B (zh) * 2009-02-10 2015-04-11 Daiichi Sankyo Co Ltd 抗－ｍｓｔ１ｒ抗體及其用途
WO2010127284A2 (en) * 2009-05-01 2010-11-04 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US20130089554A1 (en) * 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
JP2013533746A (ja) 2010-07-06 2013-08-29 アベオ ファーマシューティカルズ， インコーポレイテッド 抗ｒｏｎ抗体
KR20130100118A (ko) 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
US9046513B2 (en) 2010-08-26 2015-06-02 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
AR089529A1 (es) 2011-12-30 2014-08-27 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
WO2013173745A1 (en) * 2012-05-18 2013-11-21 Galaxy Biotech, Llc Monoclonal antibodies to macrophage stimulating protein
PE20151179A1 (es) 2012-11-01 2015-09-12 Abbvie Inc Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
AU2014227732A1 (en) 2013-03-15 2015-09-17 Abbvie Inc. Dual specific binding proteins directed against IL-1 beta and IL-17
JP6488520B2 (ja) * 2013-08-20 2019-03-27 国立研究開発法人科学技術振興機構 ヒト抗体κ型軽鎖複合体含有組成物及びその製造方法
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
WO2018052789A1 (en) 2016-09-08 2018-03-22 Pcm Targetech, Llc Monoclonal antibodies specific to the plexin-semaphorin-integrin (psi) domain of ron for drug delivery and its application in cancer therapy
AU2019205279A1 (en) * 2018-01-08 2020-07-30 Susavion Biosciences, Inc. Compositions and methods of treating cancer with glycomimetic peptides

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4275149A (en) * 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5861301A (en) * 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
AU2001264946A1 (en) * 2000-05-24 2001-12-03 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
AU2002258798A1 (en) * 2001-04-13 2002-10-28 Children's Hospital Medical Center Methods for the treatment of hepatic disorders
IL159177A0 (en) * 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
AU2003216341A1 (en) * 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
US20040101920A1 (en) * 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US20040185506A1 (en) * 2003-03-21 2004-09-23 Heavner George A. Epitope mapping using nuclear magnetic resonance

Similar Documents

Publication Publication Date Title
JP2019107018A5 (enExample)
TWI708788B (zh) 雙特異性抗體
CA2595610A1 (en) Antibodies directed to angiopoietin-2 and uses thereof
BR112020022898A2 (pt) anticorpos biespecíficos dll3-cd3
JP2010531140A5 (enExample)
JP2018504105A5 (enExample)
JP2010110329A5 (enExample)
JP2010508847A5 (enExample)
JP2009505676A5 (enExample)
JP2010510809A5 (enExample)
JP2011157397A5 (enExample)
NZ597067A (en) Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer
US20150175712A1 (en) Antagonist to an enzyme and/or a metabolite of the kynurenine pathway
CA2786479A1 (en) Methods for treating pancreatic cancer
JP2015529641A5 (enExample)
RU2012126098A (ru) Антикластериновые антитела и антигенсвязывающие фрагменты и их использование для уменьшения объема новообразований
JP2008532488A5 (enExample)
JP2008529494A5 (enExample)
JP2014515600A5 (enExample)
JP2026032010A (ja) 二重特異性抗体及びその応用
CN114650842A (zh) 抗tim-3抗体
CN117257934A (zh) 药物组合物及其用途
JP2008526256A5 (enExample)
WO2022252167A1 (en) Anti-cd98 antibodies and uses thereof
US20260103526A1 (en) Humanized anti-clec-1a antibodies and antigen-binding fragments thereof and mimetics thereof